Volume 31, Issue 10 pp. 2730-2736
ORIGINAL - DEVICES

His-bundle pacing: A novel treatment for left bundle branch block-mediated cardiomyopathy

Rajeev Singh MD, MBA

Corresponding Author

Rajeev Singh MD, MBA

Department of Cardiology, Washington University, St. Louis, Missouri, USA

Correspondence Rajeev Singh, MD, MBA, Washington University School of Medicine, 660 S Euclid Ave, Campus Box 8086, St. Louis, MO 63110, USA.

Email: [email protected]

Search for more papers by this author
Subodh Devabhaktuni MD, FACC, FHRS

Subodh Devabhaktuni MD, FACC, FHRS

Department of Cardiology, University of Arkansas Medical Sciences, Little Rock, Arkansas, USA

Search for more papers by this author
Fatima Ezzeddine MD

Fatima Ezzeddine MD

Department of Cardiology, Mayo Clinic, Rochester, Minnesota, USA

Search for more papers by this author
Joel Simon MD

Joel Simon MD

Department of Cardiology, Indiana University Health, Indianapolis, Indiana, USA

Search for more papers by this author
Kavita Khaira MD

Kavita Khaira MD

Department of Cardiology, Indiana University Health, Indianapolis, Indiana, USA

Search for more papers by this author
Gopi Dandamudi MD, MBA, FHRS

Gopi Dandamudi MD, MBA, FHRS

Department of Cardiology, CHI Pacific North West, Tacoma, Washington, USA

Search for more papers by this author
First published: 26 July 2020
Citations: 16

Disclosures: Gopi Dandamudi is a consultant and on the advisory board for Medtronic Inc and on the advisory board for Biotronik Inc. Other authors: No disclosure.

Abstract

Background

Chronic left bundle branch block (LBBB) can lead to LBBB-mediated cardiomyopathy from left ventricular dysynchrony. His-bundle pacing (HBP) results in direct electrical synchrony using the native His-Purkinje system, providing a novel treatment for this cardiomyopathy.

Objective

To assess the feasibility of HBP for cardiac resynchronization therapy (CRT) in LBBB-mediated cardiomyopathy patients.

Methods

Retrospective database review was conducted on patients who underwent CRT by the HBP capable provider at Indiana University Health and Eskenazi Hospital from August 2015 to August 2017. A subset of patients who met the predefined syndrome criteria of LBBB-mediated cardiomyopathy who underwent HBP were identified. Clinical, echocardiographic, and electrocardiographic variables were extracted at baseline and follow-up.

Results

Nine patients had cardiomyopathy and LBBB. Among those two were lost to follow-up. Seven patients were included in the analysis. The average time from device implantation to the last follow-up was 14.5 months. Left ventricular ejection fraction improved on average from 25% to 50% (p = .0001). The left ventricular end-systolic dimension decreased from 47 to 37 mm (p = .003) and the left ventricular end-diastolic dimension decreased from 55 to 48 mm (p = .03). QRS duration with HBP-CRT decreased from 152 to 115 ms. New York Heart Association classification improved from an average of 2.7–2.

Conclusion

HBP is a viable technique for pursuing CRT in patients with LBBB-mediated cardiomyopathy.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.